In conclusion, we observed pronounced intralesional spatial heterogeneity in Kras‐associated signalling activities, resulting in sensitivity to combined inhibition of PI3K–mTOR and MAPK pathways, particularly in samples and tumour subregions in which both targeted pathways are active. The gene discussed is KRAS; the disease is neoplasm.